Search results
Independent FDA Panel Endorses New Alzheimer’s Disease Treatment
WebMD· 3 days agoThe treatment can cause brain swelling or brain bleeding. Ultimately, advisors agreed that donanemab is safe and that the treatment’s benefits outweigh the risks. If fully approved, donanemab ...
AbbVie inks immune disorder drug licensing deal with China's FutureGen
AOL· 8 hours agoAbbVie has been counting on its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira following the entry of biosimilars in the U.S. The drugmaker ...
New platform streamlines epitope comparison in antibody research
Medical Xpress· 3 days agoMonoclonal antibodies are crucial therapeutics due to their high specificity and binding affinity...
Ultragenyx director Sanders Corazon sells $71,390 in company stock By Investing.com
Investing.com· 3 days agoThe shares were sold at a price of $41.10 each. Sanders Corazon, who serves as a director of...
Amid big Bayer shakeup, drugmaker loses Berkeley-based biotech chief - San Francisco Business Times
The Business Journals· 2 days agoJens Vogel, who as global head of biotech led Bayer AG's push into cell therapy manufacturing from...
Ultragenyx executive sells over $440k in company stock By Investing.com
Investing.com· 22 hours agoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) has reported a significant stock transaction by one of...
Ultragenyx (RARE) Posts New Data From Bone Disease Study
Zacks via Yahoo Finance· 1 day agoUltragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in...
RSV research: Nirsevimab 80% effective against hospitalization
Center for Infectious Disease Research and Policy· 6 days agoTwo studies highlight new respiratory syncytial virus (RSV) findings, with one estimating that the ...
Where's The Case For Generative AI In Biopharmaceutical Manufacturing?
BioresearchOnline· 2 days agoThe candidate will remain in the spotlight through its clinical journey not only because it works...
Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $40.50
ETF DAILY NEWS· 19 hours agoShares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports.